Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tiziana Life Sciences Ltd
(NQ:
TLSA
)
1.220
-0.030 (-2.40%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tiziana Life Sciences Ltd
< Previous
1
2
3
4
5
6
7
8
Next >
Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
July 27, 2023
--News Direct--
Via
News Direct
Exposures
Product Safety
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
July 21, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA)
July 10, 2023
Tiziana Life Sciences (NASDAQ: TLSA) is a biotechnology company establishing itself in a cutting-edge position in the market with its breakt
Via
Benzinga
Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company?
June 15, 2023
Company Moves Ahead With Drug Development
Via
Benzinga
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
June 13, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana's Foralumab Shown To Reduce Microglial Activation In MS Patients; Phase 2a Trial To Begin In Q3 2023
June 06, 2023
Tiziana Life Sciences Ltd.
Via
Benzinga
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
June 05, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
DeSantis Rule Shields Musk's SpaceX From Liability
May 26, 2023
Florida Gov. Ron DeSantis signed a new bill Thursday providing additional liability protections to space companies like Elon Musk's SpaceX.
Via
Investor's Business Daily
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
May 25, 2023
Webinar to take place on Monday, June 5, 2023 at 12:30 PM ET
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
May 23, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
May 17, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst
May 05, 2023
Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst
Via
News Direct
Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst
May 05, 2023
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ:TLSA). Tiziana has...
Via
TheNewswire.com
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
April 27, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
April 26, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 25, 2023
Gainers
Via
Benzinga
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
April 24, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a Trial
April 21, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer’s Disease in Q2 2023.
Via
Benzinga
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
April 20, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Via
Benzinga
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
April 18, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences’ (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise
April 17, 2023
Via
ACCESSWIRE
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
April 13, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients
April 13, 2023
Tiziana Life Sciences Ltd (NASDAQ: TLSA) plans to investigate intranasal foralumab for Long COVID. What Happened: The work is supported by foralumab's well-established role in de-activating microglia...
Via
Benzinga
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
April 12, 2023
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies...
Via
Benzinga
NIO Could Bring A Pleasant Beat This Coming Quarter
April 10, 2023
Tesla's price cuts have initiated a full on war across the EV industry, however NIO has refused to follow along. This may present even more upside for the stock
Via
MarketBeat
Topics
Electric Vehicles
Exposures
Electric Vehicles
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
April 10, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
April 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
April 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in
March 31, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.